Heineken N.V. discloses preliminary highlights of 2020 half-year results
Amsterdam, 16 July 2020 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) today issued the following statement.
In the first half of 2020, HEINEKEN’s markets and businesses were significantly impacted by the COVID-19 pandemic, with unprecedented volatility and uncertainty leading to the withdrawal of guidance for 2020 on 8 April. Despite these short-term challenges, HEINEKEN remains confident in its ability to navigate the crisis while continuing to build a bright future.
In this context, HEINEKEN has decided to disclose preliminary highlights of its 2020 half-year results ahead of the scheduled publication date. The final results will be published as planned on 3 August 2020. All figures mentioned below are preliminary, unaudited and may be subject to adjustments from customary reviews.
Based on preliminary figures, first-half net revenue (beia) declined by 16.4% on an organic basis. This is driven by an organic decline of 13.4% in total consolidated volume and an organic decline of 3.6% in net revenue (beia) per hectoliter. Beer volume declined organically by 11.5%.
As expected, the impact of the COVID-19 crisis deepened in the second quarter of 2020. After a low point in April, volume started to gradually recover into June as lockdowns were lifted around the world and customers restored depleted inventories. Beer volume was most affected in the Americas and Africa, Middle East and Eastern Europe regions with a decline in the mid-teens due to full lockdowns in Mexico and South Africa, followed by Europe with a high-single digit decline, whilst Asia Pacific showed the highest resilience driven by Vietnam.
The Heineken® brand performed well in relative terms with a 2.5% decline. The brand grew double digits in 14 markets, including Brazil, China, the UK, Poland, Germany, Ivory Coast and South Korea. Heineken® 0.0 grew double digits with growth across all regions and with particular strength in the US and Mexico.
Operating profit (beia) declined organically by 52.5%. Net profit (beia) declined by 75.8%, leading to a diluted EPS (beia) of € 0.39. Exceptional items will include around € 550 million of impairments on tangible and intangible assets, leading to a reported net loss of around € 300 million.
In Europe off-trade, beer volume grew in the mid-teens and market share increased in key markets. However, given HEINEKEN’s strong position in the on-trade and the structural differences between channels, operating profit was disproportionally affected as on-trade outlets were closed for a large part of the second quarter.
Input costs per hectoliter increased significantly with the combined negative impact of channel and product mix and transactional currency effects. From late March onwards, HEINEKEN took significant cost mitigation actions leading to an overall decrease in costs for the first half of 2020. The company is committed to further intensify its focus on costs.
HEINEKEN has entered the crisis with great brands, and a dedicated and talented workforce. The company has a strong balance sheet as well as undrawn committed credit facilities.
HEINEKEN will provide more information in its 2020 half year results report on 3 August 2020.
Note: Non-GAAP measures are used throughout this press release. Please refer to the Glossary for an explanation of the terms used.
Tim van der Zanden
Investor and analyst enquiries
Federico Castillo Martinez
HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brewing a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. It employs over 85,000 employees and operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken N.V. and Heineken Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken N.V. (OTCQX: HEINY) and Heineken Holding N.V. (OTCQX: HKHHY). Most recent information is available on HEINEKEN's website: www.theHEINEKENcompany.com and follow us on Twitter via @HEINEKENCorp.
Market Abuse Regulation:
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
This press release contains preliminary highlights of 2020 half-year results and forward-looking statements with regard to the financial position and results of HEINEKEN’s activities. The preliminary results are unaudited and may be subject to adjustments from customary reviews. The forward looking statements are also subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond HEINEKEN’s ability to control or estimate precisely, such as future market and economic conditions, developments in the ongoing Covid-19 pandemic and related government measures, the behaviour of other market participants, changes in consumer preferences, the ability to successfully integrate acquired businesses and achieve anticipated synergies, costs of raw materials, interest-rate and exchange-rate fluctuations, changes in tax rates, changes in law, change in pension costs, the actions of government regulators and weather conditions. These and other risk factors are detailed in HEINEKEN’s publicly filed annual reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only of the date of this press release. HEINEKEN does not undertake any obligation to update these forward-looking statements contained in this press release. Market share estimates contained in this press release are based on outside sources, such as specialised research institutes, in combination with management estimates.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
RESULT OF SEK CREDIT OPERATION21.9.2020 11:45:00 CEST | Press release
RESULT OF SEK CREDIT OPERATION 2020-09-21Auction date:2020-09-21Payment date:2020-09-21 (at 3 pm)Maturity date:2020-12-21Term:91 daysOffered volume:UnlimitedTotal bid amount:SEK 0 billionNumber of bids0Allotment:SEK 0 billionInterest rate:Repo rate RESULT OF SEK CREDIT OPERATION 2020-09-21Auction date:2020-09-21Payment date:2020-09-21 (at 3 pm)Maturity date:2021-03-22Term:182 daysOffered volume:UnlimitedTotal bid amount:SEK 0 billionNumber of bids0Allotment:SEK 0 billionInterest rate: Repo rate
Scandinavian Tobacco Group A/S: Transaktioner i forbindelse med aktietilbagekøbsprogram21.9.2020 10:00:00 CEST | pressemeddelelse
Selskabsmeddelelse Nr. 28/2020 København, 21. september 2020 Transaktioner i forbindelse med aktietilbagekøbsprogram Den 28. august 2020 informerede Scandinavian Tobacco Group A/S (“STG”) om iværksættelsen af et aktietilbagekøbsprogram til en samlet pris på op til DKK 300 millioner med det formål at justere selskabets kapitalstruktur og opfylde forpligtelserne i forhold til koncernens aktiebaserede incitamentsprogram. Aktietilbagekøbsprogrammet vil blive gennemført i overensstemmelse med EU-forordning nr. 596/2014 af 16. april 2014 (Markedsmisbrugsforordningen) og Kommissionens delegerede forordning (EU) 2016/1052, de såkaldte Safe Harbour-regler. Aktietilbagekøbsprogrammet slutter senest den 26. februar 2021. Følgende transaktioner er foretaget i perioden 14. september - 18. september 2020: Antal aktierGennemsnitlig købspris, DKKTransaktionsværdi, DKK Total, seneste opgørelse 283.320 28.190.854 14. september 2020 25.000 94.39 2.359.713 15. september 2020 25.000 94.50 2.362.538 16. sep
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme21.9.2020 10:00:00 CEST | Press release
Company Announcement No. 28/2020 Copenhagen, 21 September 2020 Transactions in connection with share buy-back programme On 28 August 2020, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 300 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 26 February 2021. The following transactions have been executed from 14 September to 18 September 2020: Number of sharesAverage purchase price, DKKTransaction value, DKK Accumulated, last announcement 283,320 28,190,854 14 September 2020 25,000 94.39 2,359,713 15 Sept
Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy21.9.2020 09:36:27 CEST | Press release
Hørsholm, Denmark (21 September 2020) – Oncology Venture A/S (“OV”) today announced that it will change its company name to Allarity Therapeutics (“Allarity” or the “Company”) and will significantly restructure its Board of Directors to align with the company’s current and long-term strategy. Both the proposed name change and appointment of new Board members are subject to approval of shareholders at the upcoming Extraordinary General Meeting (EGM) planned to be convened on 7 October 2020. Following the proposed restructuring, Allarity’s Board of Directors will comprise five members, including existing Directors Mr. Steve Carchedi (CEO), Mr. Duncan Moore (Chairman), and Dr. Magnus Persson, and new members in both the U.S. and Scandinavia, including Mr. Søren Gade (a current member of European Parliament and former Minister of Defense in Denmark) and Ms. Gail Maderis (current CEO of Antiva Biosciences, Inc., Board member of Valitor, Inc., and former CEO of Five Prime Therapeutics, Inc.)
Immunicum AB: Invitation to Corporate Update Event21.9.2020 08:50:00 CEST | Press release
Press Release 21 September 2020 Immunicum AB: Invitation to Corporate Update Event Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020. Investors, media and the public are welcome to join. During the event, CEO, Sven Rohmann, COO, Sijme Zeilemaker and CSO, Alex Karlsson-Parra will present an overview of Immunicum and its development priorities. Corporate Update Event Information Date: Wednesday, September 30, 2020 Time: 18.00 – 19.30 CEST The event will be livestreamed and will remain accessible in video format following the completion of the event. The link to the livestream is available here: https://www.redeye.se/events/793598/live-strategy-update-immunicum Questions can be asked prior to the event by sending an e-mail to email@example.com or through the video chat during the webcast. Preliminary Agenda: 18:00 – 18:15 Welcome 18:15 – 18:30 The exciting potential of ilixadencel and beyond 18:30 – 18:45
Immunicum AB: inbjudan till företagspresentation21.9.2020 08:50:00 CEST | Pressemelding
Pressmeddelande 21 september 2020 Immunicum AB: inbjudan till företagspresentation Immunicum AB (publ; IMMU.ST) meddelar idag att företaget kommer att hålla en livesänd företagspresentation den 30 september 2020. Investerare, media och allmänheten välkomnas att delta. Under evenemanget kommer VD Sven Rohmann, COO Sijme Zeilemaker och forskningschef Alex Karlsson-Parra att presentera en bolagsöversikt och prioriteringar för bolagets fortsatta utveckling. Information om företagspresentationen Datum: onsdagen den 30 september 2020 Tid: 18.00 - 19.30 CET Presentationen kommer att webbsändas och kommer även att finnas tillgänglig i efterhand. Länken till webbsändningen finns här: https://www.redeye.se/events/793598/live-strategy-update-immunicum Frågor kan ställas före evenemanget genom att skicka ett e-postmeddelande till firstname.lastname@example.org eller via videochatten under webbsändningen. Preliminär agenda: 18:00 - 18:15 Välkomnande 18:15 - 18:30 Ilixadencels potential och framtid 18:30 - 18:45